ischemic stroke
Conditions
Interventions
Observation group (treated with Xuesaitong Soft Capsules as monotherapy):None
Control group (treated with conventional chemical antiplatelet therapy):None
Sponsors
Dongfang Hospital, Beijing University of Chinese Medicine; Xuanwu Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) Age = 18 years, gender (unrestricted). (2) First diagnosis of ischemic stroke between January 1, 2017, and December 31, 2021. (3) Within 1 year after diagnosis, cumulative use of any study drug from the specified regimens for at least 2 months, OR within 6 months after diagnosis, cumulative use for at least 1 month. The regimens are: Conventional antiplatelet therapy with oral chemical drugs (Aspirin and/or Clopidogrel, hereinafter referred to as Chemical Drug Therapy, Control Group I). Naoxintong Capsule combined with Chemical Drug Therapy (Control Group II). Tongxinluo Capsule combined with Chemical Drug Therapy (Control Group III). Xuesaitong Soft Capsule monotherapy (Observation Group I). Xuesaitong Soft Capsule combined with Chemical Drug Therapy (Observation Group II).
Exclusion criteria
Exclusion criteria: (1) History of using any study drug prior to the first diagnosis of ischemic stroke. (2) Comorbid malignant tumor(s). (3) Use of Xueshuantong Capsule, Compound Xueshuantong Capsule, or Sanqi Shutong Capsule for =2 months within 1 year after diagnosis. (4) Missing key study information (e.g., disease diagnosis, treatment records).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1-year cardiocerebrovascular composite events; | — |
Secondary
| Measure | Time frame |
|---|---|
| 1-year all-cause mortality; | — |
Countries
China
Contacts
Public ContactChen Zhigang
Dongfang Hospital, Beijing University of Chinese Medicine
Outcome results
None listed